Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 956 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR ENLACE Study Explores Colorectal Cancer in Hispanic and Latino People October 18, 2023 Patient Guide in Testicular Cancer Now Available Also in German January 14, 2026 Ensuring a Smooth Leadership Transition at NCI April 10, 2019 National Study Examines Genetic Testing to Inform Follow-up Care for Cancer... May 7, 2026 Load more HOT NEWS Can I Have a Nonviolent Relationship with Cancer? (Part 1) Mom Of Two Diagnosed With Breast Cancer At 31: “I Just... What to Know About Returning to Work After Cancer Treatment: An... Breast cancer mortality down 66% in 20 years
